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OBJECTIVES: Parkinson’s disease (PD) affects approximately 1 million people in the 
United States. A common PD treatment is levodopa; however, motor ﬂ uctuations and 
dyskinesias are common side effects. This model examines whether rasagiline, a once-
daily irreversible monoamine oxidase type-B inhibitor for treatment of early PD, offers 
a cost-effective treatment strategy and delays the initiation of levodopa when com-
pared with ropinirole extended release (ropinirole), a once-daily dopamine agonist.
METHODS: A ﬁ ve-year Markov model was utilized to examine the cost-effectiveness
of initiating early treatment of PD with rasagiline versus ropinirole from a managed
care perspective. Strategies included initial therapy with rasagiline, followed by either
ropinirole or levodopa, versus initiating therapy with ropinirole, followed by levodopa. 
Patients could transition therapy every six months; patients on levodopa could develop
dyskinesias. Rasagiline transition probabilities obtained from the TVP-1012 in Early
Monotherapy for Parkinson’s Disease Outpatients (TEMPO) trial. Medical costs and
utility weights were from published literature. Drug costs were from Red Book. Model
outcomes included time to levodopa treatment, time to levodopa-induced dyskinesias,
life-years, quality-adjusted life-years (QALY), and incremental cost per QALY. 
One-way and probabilistic sensitivity analyses were performed. RESULTS: Compared 
to initiating treatment with ropinirole, treatment initiation with rasagiline was associ-
ated with a delay in the time to treatment with levodopa (4.45 months) and subse-
quently the time to levodopa-induced dyskinesia (1.00 months). Rasagiline initiation
was also associated with lower costs ($1660) and higher expected QALYs (0.0608) 
over 5 years, which is dominant. The model was most sensitive to clinical efﬁ cacy and
drug costs. CONCLUSIONS: Initiating treatment with rasagiline was found to delay
treatment with levodopa and subsequent dyskinesias, compared to initiating treatment
with ropinirole, and appears to be a cost-saving and clinically-effective treatment
strategy.
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A COST-CONSEQUENCES ANALYSIS OF THE IMPACT OF A-RATED
ANTI-EPILEPTIC DRUG SWITCHING: THE MANAGED CARE PLAN
PERSPECTIVE
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OBJECTIVES: Switching between FDA-approved bioequivalent anti-epileptic drugs 
(AEDs) is associated with a higher risk of epilepsy-related events possibly owing to a 
narrow therapeutic range or index (NTI). One motivation for these switches may be 
to reduce the prescription costs required to manage epilepsy. Our objective was to
characterize the annual cost impact of these switches from the payor perspective. 
METHODS: We used data from the 2006 MarketScan claims database. We com-
puted total annual costs for those with an AED switch compared to those with no
switch as the sum of total prescription claims for epilepsy treatment medications,
inpatient services, and outpatient services. We utilized multiple linear regression to
adjust the costs for age, gender, and diagnosis category. Incremental cost differences
were calculated by the addition of an A-rated AED switch indicator. RESULTS: A 
cohort of 10,464 eligible epileptics was identiﬁ ed, with 739 experiencing at least one
switch. Those with a switch were older (42.5 vs. 39.5 years), had a different regional 
distribution compared to those without a switch, but had similar gender and seizure 
diagnosis characteristics. Individual costs and consequences were estimated for pre-
scriptions: $505 (95% CI: $170, $1181), inpatient services: $316 (95% CI: $213, 
$846), and outpatient services: $214 (95% CI: $1.77, $427). Those with an A-rated 
switch had $1,036 in additional annual health care costs (95% CI: $96, $1977). This 
analysis contains limitations including a lack of adjustment for disease severity and 
no comparison of individual patients’ pre and post switch costs. CONCLUSIONS:
Those who switched between A-rated AEDs incurred more health care costs. A policy
of compulsory generic switching to reduce drug costs in this population could result
in additional expenditures of $10.8 million per year.
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OBJECTIVES: Existing assessments of the cost of Pseudomonas Aeruginosa (PA) 
infections among patients with cystic ﬁ brosis (CF) in the United Kingdom (UK) are 
incomplete and outdated. Therefore, we sought to determine the cost of PA infections 
in CF patients in the UK from a societal perspective. METHODS: We developed a 
prevalence-based model with data on age- and sex-speciﬁ c PA prevalence, health care 
utilization, other (non-medical) components of care, and productivity for CF patients. 
Using data from the medical literature, practice guidelines, National Schedule of Refer-
ence unit costs, and expert panel input, the annual per capita and total UK costs were
calculated. Direct medical and non-medical costs were calculated as the product of 1) 
the age-dependent probability that a care component is used, 2) the age-dependent 
number of units used, and 3) its unit price. Indirect costs were calculated based on
time lost from paid labor (work productivity) and unpaid labor, i.e. providing/receiv-
ing care or household work (leisure time). RESULTS: Mean total annual per capita
cost in the UK for 2007 was a22,186 [a12,945 (direct medical), a505 (direct non-
medical), and a8,735 (indirect)]. Approximately 2,400 people in the UK have CF with 
PA; therefore, the total national cost is a52.8 million (M) [(a30.8M direct medical, 
a1.2M direct non-medical, and a20.8M indirect)]. Twenty percent of the direct 
medical costs (DMC) result from acute exacerbations with 58% resulting from chronic 
care of PA infections. CONCLUSIONS: The economic burden of PA in CF patients 
is substantial. Inasmuch as 58% of this cost is for direct medical care and 39% for 
indirect costs (13% and 87% for work and leisure time lost respectively), the medical 
community, employers and patients should be attentive to policy or product innova-
tions that can diminish the incidence and burden of PA in CF, speciﬁ cally focusing on 
delaying chronic infection and preventing acute exacerbations.
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OBJECTIVES: Multiple Sclerosis (MS), a demyelinating disease of the central nervous
system, typically strikes adults during the primary productive time of their life. The 
physical and cognitive symptoms of MS can restrict individual’s physical and economic
activity resulting in a major ﬁ nancial burden on the patient, family, health system and
society. This literature review was conducted to document the global economic burden
of patients with MS. METHODS: A review of the medical literature was conducted
between January 1993 and August 2008 using the Medline, Embase, PsycInfo, HEED, 
and NHS-HEED databases. We included all studies written in the English language 
that reported any direct medical, direct non-medical, indirect, or intangible costs.
RESULTS: We identiﬁ ed 40 cost-of-illness studies which met the a priori inclusion
criteria and represented the United States, Canada, Europe, Australia, and New
Zealand. Costs associated with MS varied dramatically between countries. Comparing
studies that reported consistent cost categories indicated that disease-modifying drugs 
constituted the most important direct cost category in Australia, Belgium, France, 
Germany, Italy, Spain, Switzerland, UK and the US. In the UK, informal care was also 
an important direct cost category and in Sweden frequent use of personal assistants 
was a driver of direct costs. Studies that adopted societal perspectives estimated larger 
indirect than direct costs. Productivity losses due to early retirement and time lost
because of MS dominated the indirect costs. In general, the total cost of MS increased
with disease severity. Both direct and indirect costs were higher overall for patients
with SPMS vs. RRMS; however, these costs appeared to be related to level of disease 
severity rather than by type of MS. CONCLUSIONS: Despite differences in country-
speciﬁ c factors, all studies included in this review showed that MS constitutes a major 
ﬁ nancial burden on the patient, caregiver, health system, and society.
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OBJECTIVES: To estimate total and disease-attributable costs and resource utilization 
associated with the use of disease-modifying therapies (DMTs) by multiple sclerosis 
(MS) patients from administrative claims data. METHODS: Data from the Health-
Core Integrated Research Database were used to identify patients with q1 medical 
claims for MS (ICD-9-CM code 340.xx). The date of ﬁ rst MS claim during January
1, 2004-March 31, 2007 was deﬁ ned as the index date and patients were classiﬁ ed 
into 4 DMT treatment groups based on ﬁ rst DMT used during the post index period 
(i.e., intramuscular interferon beta-1a (IMIFB-1a), subcutaneous interferon beta-1a 
(SCIFB-1a), glatiramer acetate (GA), interferon beta-1b (IFB-1b)). All-cause and MS-
attributable costs and resource utilization associated with inpatient hospitalizations, 
emergency room visits, physician ofﬁ ce visits, other outpatient services and prescrip-
tion drug claims were determined by DMT group. Baseline patient demographic 
characteristics and comorbidities were also determined. Annualized total and MS-
attributable costs were analyzed using multivariate analysis to control for baseline
differences between groups. RESULTS: A total of 2703 MS patients (IMIFB-1a  950; 
SCIFB-1a  481; IFB-1b  378; GA  894) received DMTs during follow-up. Patient 
mean age was 43 o 10 years and 75% were female. The proportion of patients with 
q1MS-attributable hospitalization differed between groups (p  0.01), ranging from 
29.7% (IMIFB-1a) to 38.5% (SCIFB-1a). Unadjusted total annualized costs were
lowest for IMIFB-1a, $21,457, and highest for SCIFB-1a, $26,201 (p  0.01), whereas 
unadjusted annualized MS-attributable costs were lowest for IMIFB-1a, $17,370, and 
highest for SCIFB-1a, $21,617 (p  0.01). After adjusting for baseline differences, total 
annualized costs were signiﬁ cantly higher for GA ($22,394, p  0.019), and SCIFB-1a 
($24,526, p  0.0001) compared to IMIFB-1a ($21,130) while MS-attributable costs 
were signiﬁ cantly higher for SCIFB-1a ($20,942, p  0.0001) compared to IMIFB-1a 
($17,295). CONCLUSIONS: Total and MS-attributable costs were lowest for IMIFB-
1a and highest for SCIFB-1a. Economic impact, in addition to outcomes from clinical
studies, may be useful in understanding the overall beneﬁ ts of different DMTs.
